Data updated: Jun 28, 2026
Hepatitis B Clinical Trial Landscape
Hepatitis B is being studied across 629 clinical trials registered since 2008, with 128 programs currently active. The competitive pipeline includes 17 active Phase 3 trials, 51 active Phase 2 trials, and 27 active Phase 1 trials.
Top industry sponsors include Ausper Biopharma Co., Ltd., Beijing Continent Pharmaceutical Co, Ltd., GSK.
Trial activity
128 active / 629 total since 2008
Active by phase 17 Ph3 / 109 51 Ph2 / 198 27 Ph1 / 153 33 Ph4 / 169
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Ausper Biopharma Co., Ltd. 10 1 0
Beijing Continent Pharmaceutical Co, Ltd. 6 1 0
GSK 4 53 5
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 3 4 1
Brii Biosciences Limited 3 2 0
AusperBio Therapeutics Inc. 3 1 0
Fujian Akeylink Biotechnology Co., Ltd. 3 1 0
Gilead 2 27 2
Aligos Therapeutics 2 1 3
Suzhou HepaThera Biotech Co., Ltd. 2 2 0
LG Chem 2 1 0
Fujian Shengdi Pharmaceutical Co., Ltd. 2 0 0
Grand Theravac Life Sciences (Nanjing) Co., Ltd. 2 0 0
Huahui Health 1 5 1
Xiamen Amoytop Biotech Co., Ltd. 1 4 0
How the field has grown
New-trial starts peaked in 2018 (39 registered); 2025 saw 36. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (37 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 26
2017 27
2018 39
2019 27
2020 37
2021 38
2022 35
2023 33
2024 38
2025 36
2026 27
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (7) 150
2017 (4) 865
2018 (3) 504
2019 (2) 290
2020 (4) 334
2021 (2) 393
2022 (2) 919
2023 (1) 105
2024 (1) 100
2025 (7) 1,186
2026 (4) 558
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07246889 ACTIVE NOT RECRUITING
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
Ausper Biopharma Co., Ltd. n=577
NCT07343778 RECRUITING
A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis
Beijing Continent Pharmaceutical Co, Ltd. n=300
NCT07412236 NOT YET RECRUITING
A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
Beijing Continent Pharmaceutical Co, Ltd. n=1,208
NCT01651403 ACTIVE NOT RECRUITING
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
Gilead Sciences n=90
NCT07090759 RECRUITING
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment
Fujian Akeylink Biotechnology Co., Ltd. n=526
NCT07307586 RECRUITING
A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B
Zhigang Ren n=120
NCT04704024 ACTIVE NOT RECRUITING
Reducing Vertical Transmission of Hepatitis B in Africa
University of Alabama at Birmingham n=450
NCT07203118 ACTIVE NOT RECRUITING
A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B
Xi'an Xintong Pharmaceutical Research Co.,Ltd. n=1,444
NCT07095855 NOT YET RECRUITING
A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB
Shanghai Zhimeng Biopharma, Inc. n=1,300
NCT06947499 RECRUITING
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
LG Chem n=1,186
NCT05686759 RECRUITING
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
GC Biopharma Corp n=105
NCT03343431 ACTIVE NOT RECRUITING
Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection
Institut de Recherche pour le Developpement n=504
NCT06888479 NOT YET RECRUITING
Optimal Timing of Hepatitis B Vaccination After Transplants
Institute of Hematology & Blood Diseases Hospital, China n=1,500
NCT06691412 NOT YET RECRUITING
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
Assiut University n=100
NCT07588009 NOT YET RECRUITING
Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B
Fujian Akeylink Biotechnology Co., Ltd. n=576
NCT07606950 NOT YET RECRUITING
Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
Fujian Shengdi Pharmaceutical Co., Ltd. n=540
NCT00670839 COMPLETED
Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)
ANRS, Emerging Infectious Diseases n=178
NCT00823342 TERMINATED
ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy
French National Agency for Research on AIDS and Viral Hepatitis n=150
NCT05630807 COMPLETED
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
GlaxoSmithKline n=981
NCT05630820 COMPLETED
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
GlaxoSmithKline n=857
NCT04429295 COMPLETED
Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand
Sanofi Pasteur, a Sanofi Company n=460
NCT04193189 COMPLETED
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
National Institute of Allergy and Infectious Diseases (NIAID) n=638
NCT05482282 WITHDRAWN
Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)
PT Bio Farma
NCT03903796 COMPLETED
Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=963
NCT02836249 COMPLETED
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)
Gilead Sciences n=181
NCT02836236 COMPLETED
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)
Gilead Sciences n=155
NCT06544551 COMPLETED
Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection
Beijing Kawin Technology Share-Holding Co., Ltd. n=336
NCT03887702 TERMINATED
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
SWOG Cancer Research Network n=4
NCT04846491 COMPLETED
A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Xiamen Amoytop Biotech Co., Ltd. n=475
NCT01940471 COMPLETED
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
Gilead Sciences n=875
NCT01940341 COMPLETED
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
Gilead Sciences n=426
NCT02600117 COMPLETED
Use of TDF in Patients With Inactive Chronic Hepatitis B Infection
University Health Network, Toronto n=50
NCT01369212 COMPLETED
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=201
NCT02792088 COMPLETED
Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
IlDong Pharmaceutical Co Ltd n=146
NCT01519960 COMPLETED
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Hoffmann-La Roche n=165
NCT02434848 COMPLETED
A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses
Sheffield Teaching Hospitals NHS Foundation Trust n=13
NCT01251276 COMPLETED
Hepatitis B Challenge Dose in Adults (V232-059-10)
Merck Sharp & Dohme LLC n=204
NCT04490499 COMPLETED
A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
Merck Sharp & Dohme LLC n=207
NCT04209400 COMPLETED
Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®
VBI Vaccines Inc. n=100
NCT01369199 TERMINATED
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=28
NCT01368497 COMPLETED
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=60
NCT04083157 COMPLETED
Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients
The University of Hong Kong n=104
NCT02697474 COMPLETED
Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.
Sanofi Pasteur, a Sanofi Company n=150
NCT02817451 COMPLETED
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
Sanofi Pasteur, a Sanofi Company n=53
NCT02428491 COMPLETED
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
Sanofi Pasteur, a Sanofi Company n=354
NCT03627507 COMPLETED
Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.
International Centre for Diarrhoeal Disease Research, Bangladesh n=158
NCT02555943 COMPLETED
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
Humanity and Health Research Centre n=23
NCT00755950 TERMINATED
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
University of Maryland, Baltimore n=70
NCT02967939 COMPLETED
Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients
Dong-A ST Co., Ltd. n=123
NCT01745822 COMPLETED
Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand
Institut de Recherche pour le Developpement n=654
NCT02979613 COMPLETED
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
Gilead Sciences n=490
NCT02263079 COMPLETED
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
Hoffmann-La Roche n=62
NCT03393754 COMPLETED
Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults
VBI Vaccines Inc. n=1,607
NCT02759354 COMPLETED
Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
MCM Vaccines B.V. n=754
NCT01353703 COMPLETED
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine
GlaxoSmithKline n=224
NCT02096263 COMPLETED
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
GlaxoSmithKline n=585
NCT02858440 COMPLETED
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
GlaxoSmithKline n=235
NCT02058108 TERMINATED
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
Novartis Pharmaceuticals n=53
NCT01079806 COMPLETED
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection
Bristol-Myers Squibb n=180
NCT02003703 COMPLETED
Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .
Universidad de Valparaiso n=107
NCT02071082 COMPLETED
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
Gilead Sciences n=79
NCT00678587 TERMINATED
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
GlaxoSmithKline n=292
NCT01641926 TERMINATED
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
Merck Sharp & Dohme LLC n=402
NCT01463683 COMPLETED
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
Merck Sharp & Dohme LLC n=722
NCT01300234 COMPLETED
Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)
GlaxoSmithKline n=512
NCT01884415 COMPLETED
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla n=112
NCT00693186 COMPLETED
A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA
Sanofi Pasteur, a Sanofi Company n=410
NCT02012998 COMPLETED
Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA
Sanofi Pasteur, a Sanofi Company n=751
NCT01580202 COMPLETED
Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine
Seoul National University Hospital n=180
NCT01453348 COMPLETED
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
Novartis Vaccines n=252
NCT01470287 COMPLETED
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age
Novartis Vaccines n=175
NCT02094833 COMPLETED
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
Sanofi Pasteur, a Sanofi Company n=310
NCT01697501 COMPLETED
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Hoffmann-La Roche n=88
NCT00640588 COMPLETED
Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine
Novartis Pharmaceuticals n=30
NCT01694264 TERMINATED
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
Seoul National University Hospital n=43
NCT01595685 COMPLETED
Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B
Asan Medical Center n=98
NCT02249988 COMPLETED
Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B
Abivax S.A. n=261
NCT00661076 COMPLETED
ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B
Hoffmann-La Roche n=10
NCT00734162 COMPLETED
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
Gilead Sciences n=106
NCT01480284 COMPLETED
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue
GlaxoSmithKline n=166
NCT00654901 COMPLETED
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
Sanofi Pasteur, a Sanofi Company n=881
NCT00831753 COMPLETED
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants
Sanofi Pasteur, a Sanofi Company n=263
NCT00737568 COMPLETED
Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine
Gilead Sciences n=280
NCT01131065 COMPLETED
Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients
Instituto Grifols, S.A. n=15
NCT00800787 WITHDRAWN
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
Biotest Pharmaceuticals Corporation
NCT01983540 COMPLETED
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
Sanofi Pasteur, a Sanofi Company n=558
NCT01948193 COMPLETED
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth
Sanofi Pasteur, a Sanofi Company n=177
NCT01760122 COMPLETED
Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
Xiamen Amoytop Biotech Co., Ltd. n=820
NCT01475851 COMPLETED
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
GlaxoSmithKline n=34
NCT01513850 COMPLETED
A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients
SK Chemicals Co., Ltd. n=87
NCT01856413 COMPLETED
A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant
Biotest n=49
NCT01063036 COMPLETED
Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment
Bristol-Myers Squibb n=144
NCT01046799 COMPLETED
Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir
HepNet Study House, German Liverfoundation n=20
NCT01872988 TERMINATED
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Taichung Veterans General Hospital n=320
NCT01444781 COMPLETED
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
Sanofi Pasteur, a Sanofi Company n=1,106
NCT01917357 COMPLETED
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
Crucell Holland BV n=400
NCT02152709 COMPLETED
Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine
Jiangsu Province Centers for Disease Control and Prevention n=1,537
NCT01177722 COMPLETED
A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants
Sanofi Pasteur, a Sanofi Company n=1,375
NCT01349283 COMPLETED
Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns
Crucell Holland BV n=1,738
NCT00410202 COMPLETED
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
Bristol-Myers Squibb n=629
NCT01892241 COMPLETED
Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
Third Affiliated Hospital, Sun Yat-Sen University n=74
NCT01362517 COMPLETED
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B
Crucell Holland BV n=131
NCT00805675 COMPLETED
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
Novartis Pharmaceuticals n=83
NCT00605384 TERMINATED
A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection
Bristol-Myers Squibb n=4
NCT00480116 COMPLETED
Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule
Henogen n=450
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only